A recent proposal that calls for reducing the benefits of the 340B Drug Pricing Program to curb rapidly rising prescription drug costs is “misguided,” writes AHA Executive Vice President Tom Nickels in an AHASTAT blog post today. Responding to a recent opinion piece in the New England Journal of Medicine, Nickels said, “The 340B program is more important now than ever before as the prices of prescription drugs continue to skyrocket. Instead of trying to make changes to a program with a strong track record of increasing access to care for patients in vulnerable communities, policymakers should consider other solutions, such as requiring greater transparency on drug pricing and charity policies by drug companies, increased competition in the generic industry or other reasonable proposals.” For more on the 340B program, visit www.aha.org/protect340B.

Related News Articles

Headline
Rural Americans live an average 10.5 miles or 17 minutes from the nearest hospital, according to a new analysis by the Pew Research Center.
Headline
The Medicare Payment Advisory Commission this week discussed several draft recommendations for Congress, which the panel could vote on in January.
Headline
AHA today urged the Department of Homeland Security to withdraw a proposed rule that could limit legal immigrants’ future immigration status if they receive…
Headline
Hospitals participating in the Medicare Comprehensive Care for Joint Replacement model are more likely to implement programs to improve post-discharge care and…
Headline
The Centers for Medicare…
Headline
As urged by the AHA, the Health Resources and Services Administration today announced that it expects to publish online by April 1 drug ceiling prices under…